PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine

Vaccine

Volumn 31, Issue 5, 2013, Pages 850-856

  Sanders, Barbara P ^a   Edo Matas, Diana ^a   Custers, Jerome H H V ^a   Koldijk, Martin H ^a   Klaren, Vincent ^a   Turk, Marije ^b   Luitjens, Alfred ^a   Bakker, Wilfried A M ^c   Uytdehaag, Fons ^a   Goudsmit, Jaap ^a   Lewis, John A ^a   Schuitemaker, Hanneke ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b Bioscience Park Leiden   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

IPV; PER.C6 cells; Poliomyelitis; Poliovirus; Vaccine

Indexed keywords

POLIOMYELITIS VACCINE; VIRUS ANTIGEN;

ARTICLE; BIOREACTOR; CELL CULTURE; CELL DENSITY; CELL GROWTH; CELL LINE; CELL SUSPENSION; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN CELL; NONHUMAN; PER C6 CELL; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEROTYPE; VACCINE PRODUCTION; VERO CELL; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL LINE; CULTURE MEDIA, SERUM-FREE; HUMANS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; TECHNOLOGY, PHARMACEUTICAL; VIRAL LOAD; VIRUS CULTIVATION;

EID: 84872602323     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.070     Document Type: Article

References (46)

1. Roberts L. Polio endgame. Polio: the final assault?. Science 2004, 303(5666):1960-1968.
2. WHO. Polio this week: Consulted October 2012. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
3. Sabin A.B. Properties and behavior of orally administered attenuated poliovirus vaccine. JAMA 1957, 164(11):1216-1223.
4. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26(39):4978-4983.
5. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 2009, 8(1):5-8.
6. Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002, 296(5566):356-359.
7. Henderson D.A., Witte J.J., Morris L., Langmuir A.D. Paralytic disease associated with oral Polio vaccines. JAMA 1964, 13:1335-1340.
8. Dick G. Immunity to poliomyelitis. Br Med J 1963, 2(5370):1468-1469.
9. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010, 172(11):1213-1229.
10. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27(20):2649-2652.
11. Combelas N., Holmblat B., Joffret M.L., Colbere-Garapin F., Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses 2011, 3(8):1460-1484.
12. WHO Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 2006, 81(15):137-144.
13. Salk J.E., Krech U., Youngner J.S., Bennett B.L., Lewis L.J., Bazeley P.L. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health 1954, 44(5):563-570.
14. John T.J. Anomalous observations on IPV and OPV vaccination. Dev Biol (Basel) 2001, 105:197-208.
15. Robertson S.E., Traverso H.P., Drucker J.A., Rovira E.Z., Fabre-Teste B., Sow A., et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988, 1(8591):897-899.
16. Dhillon S. Spotlight on DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). BioDrugs 2010, 24(5):299-302.
17. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28(22):3778-3783.
18. Zehrung D. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries. An economic analysis of strategies to reduce the cost of routine IPV immunization 2010, PATH.
19. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009, 8(5):607-618.
20. Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998, 9(13):1909-1917.
21. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19(17-19):2716-2721.
22. Koldijk M.H., Bogaards J.A., Kostense S., de Vocht M., Gijsbers L., Ter Haak M., et al. A sensitive cell-based assay for the detection of residual infectious West Nile virus. Vaccine 2007, 25(39-40):6872-6881.
23. Yallop C.C.J., Cote J., Hegmans-Brouwer K., Lagerwerf F., Gagne R., Martin J.C., et al. Per.C6 cells for the manufacture of biopharmaceutical proteins. Modern biopharmaceuticals 2005, vol. 3.
24. Sabin A.B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985, 151(3):420-436.
25. Enders J.F.W., Robbins T.H. F.C. Alteration in pathogenicity for monkeys of the Brunhilde strain of Poliomyelitis virus following cultivation in human tissues. Fed Proc 1952, 11(467).
26. Hamilton M.A., Russo R.C., Thurston R.V. Trimmed Spearman-Karber method for estimating median lethal concentration in toxicity bioassays. Environ Sci Technol 1977, 11:714-719.
27. Montagnon B.J., Fanget B., Nicolas A.J. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981, 47:55-64.
28. van Wezel A.L., van Herwaarden J.A., van de Heuvel-de Rijk E.W. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 1979, 42:65-69.
29. van Wezel A.L., van Steenis G., van der Marel P., Osterhaus A.D. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 1984, 6(Suppl. 2):S335-S340.
30. Duchene M., Peetermans J., D'Hondt E., Harford N., Fabry L., Stephenne J. Production of poliovirus vaccines: past, present, and future. Viral Immunol 1990, 3(4):243-272.
31. Dowdle W.R., De Gourville E., Kew O.M., Pallansch M.A., Wood D.J. Polio eradication: the OPV paradox. Rev Med Virol 2003, 13(5):277-291.
32. Duchene M. Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view. Biologicals 2006, 34(2):163-166.
33. Venczel L, Landry S, Aylward B, Sutter R, Sabow A, Smith G. Global post-eradication IPV supply and demand assessment: integrated findings - commissioned by the Bill & Melinda Gates foundation. Oliver Wyman, Inc.; 2009.
34. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362(25):2351-2359.
35. WHO. Update on improving IPV. The Polio Pipeline 2009;3:3.
36. Lubiniecki A.S. Elimination of serum from cell culture medium. Dev Biol Stand 1999, 99:153-156.
37. Froud S.J. The development, benefits and disadvantages of serum-free media. Dev Biol Stand 1999, 99:157-166.
38. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34(2):155-158.
39. Choi S.K., Chang H.N., Lee G.M., Kim I.H., Oh D.J. High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system. Cytotechnology 1995, 17(3):173-183.
40. Trabelsi K., Rourou S., Loukil H., Majoul S., Kallel H. Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor. Enzyme Microb Technol 2005, 36:514-519.
41. Gelbgras V., Wylock C.E., Drugmand J., Haut B. Structured model of VERO cells metabolism in a fixed-bed bioreactor. Chem Prod Process Model 2011, 6(1):1-34.
42. Chen A., Poh S.L., Dietzsch C., Roethl E., Yan M.L., Ng S.K. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells. BMC Biotechnol 2011, 11:81.
43. Cinatl J., Cinatl J., Rabenau H., Rapp J., Kornhuber B., Doerr H.W. Protein-free culture of Vero cells: a substrate for replication of human pathogenic viruses. Cell Biol Int 1993, 17(9):885-895.
44. Rourou S., van der Ark A., Majoul S., Trabelsi K., van der Velden T., Kallel H. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor. Appl Microbiol Biotechnol 2009, 85(1):53-63.
45. Rourou S., van der Ark A., van der Velden T., Kallel H. Development of an animal-component free medium for Vero cells culture. Biotechnol Prog 2009, 25(6):1752-1761.
46. Beale A.J. The D-antigen content in poliovaccine as a measure of potency. Lancet 1961, 2(7213):1166-1168.